Holen Sie sich die Stockscreener-App
4.54
3.40%
-0.16
Handel nachbörslich:
4.55
0.010
+0.22%
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK
Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz
Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer
Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals
Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks
Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus
APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate
Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter
Aptevo, Niowave form 50/50 partnership for cancer drugs By Investing.com - Investing.com Nigeria
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, I - PharmiWeb.com
Aptevo, Niowave form 50/50 partnership for cancer drugs - Investing.com
Niowave takes 7.9% Aptevo stake in cancer radiopharma tie-up - Stock Titan
APVO Q1 2026 Earnings: Stock Rises Despite Wider-Than-Expected Loss as Pipeline Progress Takes Center Stage - The Legal Advocate
APVO Q1 2026 Earnings: Stock Gains Sharply Despite Wider-Than-Expected LossShare Dilution Risk - The Legal Advocate
Aptevo (APVO) Q1 2026 Earnings: Soft Quarter Raises QuestionsEarnings Miss Alert - Newser
All you need to know about Aptevo Therapeutics (APVO) rating upgrade to buy - MSN
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - Yahoo Finance
Aptevo (APVO) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Consistency Score - Newser
Key facts: Aptevo Q1 loss $0.01/sh; mipletamig shows 87% clinical benefit - TradingView
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports clinical trial results for AML drug candidate By Investing.com - Investing.com India
Aptevo (APVO) Positioned for Growth with Promising Pipeline and Leadership - GuruFocus
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo Therapeutics (NASDAQ: APVO) warns on going concern after $6.7M Q1 loss - Stock Titan
Strong AML data and $60M equity facility in Aptevo (NASDAQ: APVO) Q1 update - Stock Titan
Aptevo Therapeutics Updates on Q1 2026 Progress and Leadership T - GuruFocus
Aptevo reports clinical trial results for AML drug candidate - Investing.com UK
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire
Leukemia trial hits 81% remission; Aptevo lines up $60M equity line - Stock Titan
APVO Price Today: Aptevo Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
Number of shareholders of Aptevo Therapeutics, Inc. – GETTEX:AP82 - TradingView
10-K - SEC.gov
Aptevo Therapeutics Inc expected to post a loss of $5.60 a shareEarnings Preview - TradingView
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):